Report Id: SNS/HC/1014 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Blood Testing Market Size was valued at USD 2.51 billion in 2022 and is expected to reach USD 4.69 billion by 2030, and grow at a CAGR of 8.1% over the forecast period 2023-2030.
Blood testing is a lab test procedure that determines the state of a patient's health by taking a blood sample from the patient's body with syringes or a fingertip prick. Blood tests can be used to determine how well organs are working. These tests are cheaply priced and are typically performed in clinics and hospitals as a vital checkup for recognizing any mild to severe illnesses, which has an impact on the blood testing market's growth. In recent years, the blood testing industry has experienced tremendous expansion. The influence of the world's aging population is driving the market's expansion. The number of strategic acquisitions and mergers in the global market has recently increased dramatically, causing industry leaders' product portfolios to expand and their marketing power to strengthen.
Additionally, factors such as the expanding use of blood testing in other diagnostic areas and the rise in the occurrences of various diseases like bacterial and viral allergic disorders, cancer, Human Immunodeficiency Virus (HIV) infection, thyroids, genetic disorders, and hepatitis are expected to boost market efficiency over the forecasted period. On the other side, the market's growth will be hampered in the coming years by a lack of awareness of recent advancements, regulatory approval processes, and the high cost of automated blood testing.
MARKET DYNAMICS:
DRIVERS
Rise in the number of blood donation
RESTRAINTS
Technology alternatives
OPPORTUNITIES
Emerging market
CHALLENGES
Blood screening devices are expensive.
IMPACT OF COVID-19:
The beginning of the COVID-19 pandemic has changed clinical consideration conveyance all over the planet. Many hospitals and departments have been re-profiled for treating COVID-19 patients due to increased pressure from the rising rate of COVID-19 hospitalizations. The COVID-19 epidemic prompted worldwide curfews and lockdowns, halting blood donations, canceling collecting drives, and reducing demand for given blood. It modestly affects the market for blood screening. As curfews and social confinement become less severe, a request is probably going to rise, bringing about a market shortage. Governments around the world are, though, taking steps to increase donations during the anticipated period in order to meet the unexpected surge in need following the shutdown.
Furthermore, the number of cancer patients is rising, increasing the demand for donated blood. Blood and platelets are required for cancer patients' treatment (chemotherapy), blood replacement (for blood cancer patients), and surgery.
By Product and Service
Reagents and kits, devices, and software and services make up the blood screening market. In 2021 reagents and kits held the biggest part of the blood screening market, owing to an increase in blood transfusion operations, which resulted in increased consumption and repeated usage of reagents and kits in blood screening processes.
By Technology
The nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), fast tests, western blot assays, and next-generation sequencing (NGS) segments of the blood screening business. The nucleic acid test (NAT) category will account for the majority of the blood screening market by 2020. Reasons like the expanding volume of blood donations and the increasing acceptance of NAT technology due to its higher sensitivity than other blood screening technologies.
By End-User
The blood screening industry is divided into two categories: blood banks and hospitals. The blood banks category held the highest share of the blood screening market in 2021. The increasing number of organ transplant surgeries is propelling this market forward.
COMPETITIVE LANDSCAPE:
Some of the major key players are as follows: Abbott, Bio-Rad Laboratories, Inc., Trinity Biotech Plc, F. Hoffmann-La Roche AG, BioMerieux SA, Biomerica, Inc., Quest Diagnostics, Danaher Corporation, Siemens Healthineers, Becton, Dickinson, and Company.
KEY MARKET SEGMENT:
By Product and Service
1. Reagents & Kits
2. Instruments
3. Software & Services
By Technology
1. Nucleic Acid Test
Real-time PCR
Transcription-mediated Amplification
2. ELISA
Fluorescent Immunoassays
Chemiluminescent Immunoassays
Colorimetric Immunoassays
3. Rapid Tests
4. Next-generation Sequencing
5. Western Blot Assays
By End-User
REGIONAL ANALYSIS
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five key regions that make up the worldwide blood screening market. North America held the highest share of the blood screening market in 2021. The rise of the North American blood screening market can be due to rising healthcare spending, rising chronic disease prevalence, and the highly developed healthcare systems in the United States and Canada.
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Report Attributes | Details |
---|---|
Market Size in 2022 | US$ 2.51 Billion |
Market Size by 2030 | US$ 4.69 Billion |
CAGR | CAGR of 8.1% From 2023 to 2030 |
Base Year | 2022 |
Forecast Period | 2023-2030 |
Historical Data | 2020-2021 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
Key Segments | • By Product and Service (Reagents & Kits (NAT Reagents & Kits, Other Reagents & Kits, ELISA Reagents & Kits) • By Instruments (Outright Purchase, Rental Purchase), Software & Services) • By Technology (Nucleic Acid Test, ELISA, Rapid Tests, Next-generation Sequencing, Western Blot Assays) • By End User (Hospitals, Blood Banks) |
Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Company Profiles | Abbott, Bio-Rad Laboratories, Inc., Trinity Biotech Plc, F. Hoffmann-La Roche AG, BioMerieux SA, Biomerica, Inc., Quest Diagnostics, Danaher Corporation, Siemens Healthineers, Becton, Dickinson, and Company. |
DRIVING FACTORS | • Rise in the number of blood donation |
Restraints | • Technology alternatives |
Frequently Asked Questions (FAQ) :
The blood Testing market is expected to grow at a CAGR of 8.1% over the forecast period 2022-2028.
Technology alternatives are the restraints of the Blood Testing market.
The blood Testing Market is divided into two segments and they are By Product and Service, By Technology, By End User.
The market for Blood Testing was dominated by North America.
Manufacturer and service provider, research institutes, universities, and private libraries, suppliers, and distributors.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Blood Testing Market Segmentation, Product and Service
8.1 Reagents & Kits
8.2 NAT Reagents & Kits
8.3 Other Reagents & Kits
8.4 ELISA Reagents & Kits
8.5 Instruments
8.6 Outright Purchase
8.7 Rental Purchase
8.8 Software & Services
9. Blood Testing Market Segmentation, by Technology
9.1 Nucleic Acid Test
9.2 Real-time PCR
9.3 Transcription-mediated Amplification
9.4 ELISA
9.5 Fluorescent Immunoassays
9.6 Chemiluminescent Immunoassays
9.7 Colorimetric Immunoassays
9.8 Rapid Tests
9.9 Next-generation Sequencing
9.10 Western Blot Assays
10. Blood Testing Market Segmentation, By End User
10.1 Hospitals
10.2 Blood Banks
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 USA
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 South Korea
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.1 Israel
11.5.2 UAE
11.5.3 South Africa
11.5.4 Rest
11.6 Latin America
11.6.1 Brazil
11.6.2 Argentina
11.6.3 Rest of Latin America
12. Company Profiles
12.1 Abbott
12.1.1 Financial
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Bio-Rad Laboratories, Inc.
12.3 Trinity Biotech Plc
12.4 F. Hoffmann-La Roche AG
12.5 BioMerieux SA
12.6 Biomerica, Inc.
12.7 Quest Diagnostics
12.8 Danaher Corporation
12.9 Siemens Healthineers
12.10 Becton
12.11 Dickinson and Company
13. Competitive Landscape
13.1 Competitive Benchmark
13.2 Market Share Analysis
13.3 Recent Developments
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.